Key takeaways:
Zepbound (tirzepatide) is a once-weekly injection that’s FDA approved for weight loss and obstructive sleep apnea. Some people may have trouble filling prescriptions for Zepbound, so they may be looking for alternatives.
Injectable Zepbound alternatives include Wegovy (semaglutide) and Saxenda (liraglutide). These are the most similar weight-loss alternatives, but people may run into similar issues filling prescriptions for them. Saxenda is currently in shortage and may be difficult to find at some pharmacies.
Oral Zepbound alternatives include Contrave (naltrexone / bupropion), Qsymia (phentermine / topiramate ER), and Xenical (orlistat). These medications are more readily available, but they may not provide as much weight loss as Zepbound.
Zepbound (tirzepatide) is one of several FDA-approved weight-loss medications. It’s currently also the only medication that’s approved to treat obstructive sleep apnea (OSA) for adults with larger bodies. This once-weekly injection mimics the effects of two natural gut hormones: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Taking Zepbound has led to significant weight loss for many people.
Zepbound quickly grew in popularity after its FDA approval, resulting in a shortage. This shortage has been resolved. But between pharmacies not having it in stock and insurance plans not always covering it, you may still have difficulty getting Zepbound. Plus, there’s currently no available generic for Zepbound. This has many people looking at other options.
But what’s available for chronic weight management? Below, we’ll review five Zepbound alternatives your prescriber may discuss with you.
Wegovy (semaglutide) is very similar to Zepbound. It’s also a once-weekly injection that can provide significant weight loss. But Wegovy only acts like one gut hormone: GLP-1. Zepbound is currently the only FDA-approved weight-loss medication that acts like both GLP-1 and GIP.
This difference in how each works means that Zepbound may provide greater weight loss than Wegovy for some people. A head-to-head clinical trial found that people using Zepbound lost more weight than those using Wegovy (20% versus 14% of your starting body weight).
Keep in mind that Wegovy isn’t approved for OSA. So if you’re using Zepbound to manage this condition, you may not be able to switch to Wegovy.
Wegovy has a few notable differences from Zepbound. Beyond weight loss, it’s also approved to lower the risk of serious cardiovascular problems for adults considered to be overweight or obese and who also have heart disease. Zepbound’s cardiovascular benefits are still being studied. If you also have heart disease, your prescriber may switch you to Wegovy for its added heart benefits. It may also be more likely to be covered by insurance for this reason.
Wegovy also has the advantage of being approved for adults and adolescents ages 12 and older. Zepbound is still being studied for use in children, so it’s currently only approved for adults.
When prescribed for weight loss alone, Wegovy has similar insurance coverage issues as Zepbound. And because Wegovy is also a popular medication, pharmacies may not have it readily available either. So while this could be the most ideal Zepbound alternative for you, it may be difficult to fill a prescription for it.
Good to know: You can access Wegovy through NovoCare Pharmacy for $499 per month and have the medication shipped directly to you. This may be an option if you’re having trouble filling your prescription at your local pharmacy, or if your insurance doesn’t cover it.
Saxenda (liraglutide) is another weight-loss injection. It belongs to the same class as Wegovy and acts like the gut hormone GLP-1 in the body. But unlike Zepbound and Wegovy, you’ll need to inject Saxenda once a day.
Similar to Zepbound, Saxenda doesn’t have proven cardiovascular benefits. But Saxenda isn’t approved for OSA. However, it is approved for weight loss in adolescents ages 12 and older with larger bodies.
Based on individual clinical trials, Zepbound may cause more weight loss than Saxenda. People taking Zepbound for 72 weeks (16.5 months) in clinical trials lost an average of 15% to 20% of their starting body weight. People taking Saxenda for 56 weeks (almost 13 months) lost an average of 8% of their body weight. But keep in mind that these medications haven’t been compared directly in a head-to-head clinical trial.
If you switch from Zepbound to Saxenda, be aware that their injection pens are different. Zepbound’s pen comes with a needle already attached to it and is meant for a single use. You will discard the pen in a sharps container after you inject it. Saxenda’s pen, however, is meant for multiple uses. So before each Saxenda dose, you will attach a fresh pen needle.
Compare options: Zepbound and Wegovy have a few notable differences. Read more about how they compare for weight loss.
How it works: Zepbound mimics the effects of two gut hormones, which helps promote weight loss. Read about how Zepbound works here.
Standard dosages: To limit side effects, it’s recommended to start with a low Zepbound dose and gradually raise it. Read more about the typical Zepbound dosage schedule.
Currently, there’s a shortage of Saxenda. So it could be tough to find a pharmacy who has it in stock.
Contrave is a potential oral Zepbound alternative. Contrave is a tablet that contains two medications: naltrexone and bupropion. These active ingredients work together to help lower your appetite and reduce food cravings. It may be helpful if you experience emotional eating.
After the first few weeks of taking Contrave, the standard dosage is 2 pills twice a day. In general, people typically lose less weight with oral weight-loss medications than injections, such as Zepbound. On average, people taking Contrave in studies lost between 5% and 8% of their starting body weight.
Contrave has different risks and side effects than Zepbound. For instance, both can cause stomach upset and diarrhea. But Contrave can also cause trouble sleeping and higher blood pressure. You may not be able to take Contrave if you have a history of seizures or an eating disorder. Contrave also has unique interactions to consider.
If you’re changing from Zepbound to Contrave, it’s a good idea to review your full medical history and medication list with your prescriber. They can use this information to let you know if you can safely make the switch.
Currently, there’s no shortage of Contrave, and it seems to be more readily available than injectable weight-loss medications. So you might have an easier time finding a pharmacy that has it in stock.
Qsymia (phentermine / topiramate ER) is another oral Zepbound alternative. Like Contrave, it’s a combination pill. The two medications — phentermine and topiramate — work together to reduce your appetite.
Qsymia’s typical dosage may be more convenient for some people than Contrave’s. You typically take 1 pill once a day in the morning. As with other oral options, you may lose less weight with Qsymia than with Zepbound. Most people lost about 8% to 10% of their starting body weight while taking Qsymia in clinical trials.
You and your prescriber should discuss Qsymia’s side effects, risks, and interactions before switching to it. This medication commonly causes numbness or tingling, constipation, and dry mouth.
Qsymia can also cause severe birth defects. Because of this, there’s a mandatory risk management program for the medication. If you’re able to get pregnant, you’ll have to take a pregnancy test before starting Qsymia, and then subsequently once a month for as long as you’re taking it. You’ll also need to use an effective form of birth control while taking Qsymia.
There’s no shortage of Qsymia right now. So it should be readily available. But because of Qsymia’s risk management program, pharmacies must be certified through the FDA to dispense it. So not all pharmacies may be able to fill a prescription for it.
Another oral Zepbound alternative to consider is Xenical (orlistat). Its active ingredient is also available over the counter in lower doses under the brand name Alli.
Xenical works differently than the other Zepbound alternatives discussed above. It blocks your body from absorbing fat from the foods you eat. But in order for it to be effective, you need to take Xenical 3 times daily with meals that contain fat. On average, people lost about 8.5% of their starting body weight when taking Xenical in clinical trials.
Xenical can cause some uncomfortable side effects. These include:
Loose or oily stools
Stomach pain
Gas with oily spotting
Xenical can also prevent your body from absorbing certain vitamins from your diet. It’s common for prescribers to recommend taking a multivitamin if you’re also taking Xenical. It can also interfere with how your body absorbs other medications you’re taking.
Similar to the oral weight-loss medications listed above, there’s no shortage of Xenical. It should be readily available for pharmacies to order and dispense.
No, the FDA determined that the Zepbound shortage ended in October 2024. This decision was initially challenged. But the agency upheld their decision in December 2024.
But just because the Zepbound shortage is over, that doesn’t mean it’s always easy to find. Some pharmacies may still have problems keeping up with the high demands. It’s a good idea to call your pharmacy at least 1 week ahead of when you’ll need to refill your Zepbound prescription. This will give them more time to order it for you.
Eli Lilly (the manufacturer) offers vials of Zepbound directly through their website (called LillyDirect). This can help ensure that your medication is available when you need it. And it can help lower costs if your insurance plan doesn’t cover Zepbound. Lower-cost single-dose vials are available through LillyDirect for $349 (2.5 mg) and $499 (5 mg, 7.5 mg, and 10 mg) per month.
It depends on what health conditions you have. Ozempic (semaglutide) and Mounjaro (tirzepatide) are approved for adults to manage Type 2 diabetes. Ozempic is also approved to lower the risk of:
Serious cardiovascular problems for adults with Type 2 diabetes and heart disease
Worsening kidney function, kidney failure, and cardiovascular death for adults with Type 2 diabetes and chronic kidney disease
If you also have Type 2 diabetes, you may qualify to use Ozempic or Mounjaro. And your insurance plan may cover them differently than Zepbound.
Both Ozempic and Mounjaro can cause significant weight loss. But they’re not approved for this use. However, some healthcare professionals may prescribe them off-label for weight loss.
No, there’s currently no pill form of Zepbound available. Rybelsus is an oral version of semaglutide (Ozempic, Wegovy). It’s approved for Type 2 diabetes. And it’s likely to be approved for weight loss (as oral Wegovy) in the near future.
The combination of Zepbound with other weight-loss medications hasn’t been well studied. But it’s possible your prescriber may suggest using Zepbound and an oral weight-loss pill. They’ll consider your personal risks when making this recommendation.
You shouldn’t use Zepbound with other GLP-1 receptor agonists, such as Wegovy or Saxenda. Zepbound works similarly to these medications. Combining them can raise your risk of side effects, such as nausea or diarrhea.
Maybe. Everyone responds differently to Zepbound. So you may not lose as much weight as other people using it. It’s possible your prescriber may suggest switching to a different weight-loss medication to see if you respond better. Speak with your healthcare team if you’re not seeing the results you expected. But keep in mind that weight loss with Zepbound is gradual. It can take weeks or months before you experience noticeable changes.
Zepbound (tirzepatide) is a once-weekly weight-loss injection that’s grown in popularity since its FDA approval. It’s no longer in shortage, but availability at pharmacies and insurance coverage issues have some people looking for alternatives.
Injectable Zepbound alternatives, such as Wegovy (semaglutide) and Saxenda (liraglutide), are the most similar options. But they may have similar availability or coverage barriers. Oral Zepbound alternatives are more readily accessible but may not result in as much weight loss. These include Contrave (naltrexone / bupropion), Qsymia (phentermine / topiramate ER), and Xenical (orlistat).
Each Zepbound alternative has unique risks, side effects, and interactions. They also provide different amounts of weight loss. Discuss which option may be right for you with your prescriber.
ClinicalTrials.gov. (2025). A study of tirzepatide (LY3298176) once weekly in adolescent participants who have obesity or overweight with weight-related comorbidities. National Library of Medicine.
Eli Lilly and Company. (2025). Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients.
Eli Lilly and Company. (2025). Zepbound- tirzepatide injection, solution [package insert]. DailyMed.
Eli Lilly and Company. (2025). Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine.
Finer, N., et al. (2000). One-year treatment of obesity: A randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. International Journal of Obesity.
Gadde, K. M., et al. (2011). Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): A randomised, placebo-controlled, phase 3 trial. The Lancet.
H2-Pharma. (2024). Xenical- orlistat capsule [package insert]. DailyMed.
Haleon US Holdings. (2024). Alli- orlistat capsule [package insert]. DailyMed.
Jastreboff, A. M., et al. (2022). Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine.
NovoCare. (n.d.). What NovoCare Pharmacy offers.
Novo Nordisk. (2024). Wegovy- semaglutide injection, solution [package insert]. DailyMed.
Novo Nordisk. (2025). Ozempic- semaglutide injection, solution [package insert]. DailyMed.
Pi-Sunyer, X., et al. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. The New England Journal of Medicine.
Qsymia. (n.d.). Risk of birth defects with Qsymia.
Sherman, M. M., et al. (2016). Naltrexone/bupropion ER (Contrave). Pharmacy and Therapeutics.
U.S. Food and Drug Administration. (2025). FDA drug shortages.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.